Ironwood Pharmaceuticals, Inc.’s IRWD share price has dipped by 15.22%, which has investors questioning if this is right time ...

More information: Bin Zhang et al, Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow ...

The trial drug, ataciguat (HMR 1766, R Bio), is the first drug able to bind to oxidized soluble guanylate cyclase (sGC), the main receptor for nitric oxide, and reactivate the molecule.

After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...

The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis in phase I and II studies.

Stephen, R., Palczewski, K., Sousa, M.C. (2008) Ca2+-dependent regulation of phototransduction. Photochem. And Photobiol. 84. 903-910 Stephen, R. (2008) Structural ...